The phenotypic similarities between hepatocyte-Srebf-2-/- and hepatocyte-Scap-/- mice also suggest that blocking SREBP-2 action would be effective in preventing the development of hepatic steatosis in mice with insulin resistance and/or diabetes. Here, SCAP is linked to fatty liver disease.